GH director receives RSUs, company withholds 14,602 shares at $62.48/$62.65

Rhea-AI Filing Summary

Guardant Health director and Co‑Chief Executive Officer AmirAli Talasaz reported multiple transactions in the company's common stock. On 09/30/2025 he received 4,814 shares from vesting of restricted stock units and, separately the same day, 2,440 shares were retained by the company to satisfy tax withholding at a reported price of $62.48. On 10/01/2025 he received an additional 23,997 vested shares and 12,162 shares were retained for tax withholding at $62.65. After these reported transactions his beneficial ownership rose to 2,010,036 shares.

Positive

• Beneficial ownership increased to 2,010,036 shares after reported transactions
• Received vested RSUs totaling 28,811 shares on 09/30/2025 and 10/01/2025 (4,814 + 23,997)

Negative

• Company retained shares for tax withholding totaling 14,602 shares (2,440 + 12,162), reducing net shares delivered
• Retained shares were sold at market prices of $62.48 and $62.65, indicating withholding rather than voluntary sale

Insights

Corporate Governance Analyst

Insider received RSU vesting and retained shares for tax withholding; total holdings increased to 2,010,036.

These entries combine restricted stock unit vesting (codes M) and company retention of shares to cover tax withholding (code F). The filings show vested shares of 4,814 and 23,997 on 09/30/2025 and 10/01/2025, respectively.

This is administrative compensation-related activity rather than open-market purchases or strategic dispositions; retained shares reduced the net received amounts but did not indicate voluntary sale for cash.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Talasaz AmirAli

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		M		4,814	A	$0	1,988,479	D
Common Stock	09/30/2025		F		2,440(1)	D	$62.48	1,986,039	D
Common Stock	10/01/2025		M		23,997	A	$0	2,010,036	D
Common Stock	10/01/2025		F		12,162(1)	D	$62.65	1,997,874	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	09/30/2025		M			4,814	(2)	(3)	Common Stock	4,814	$0	4,815	D
Restricted Stock Units	$0	10/01/2025		M			23,997	(4)	(3)	Common Stock	23,997	$0	119,986	D

Explanation of Responses:

1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.

2. This represents a restricted stock unit award granted on March 12, 2025 that vests in four equal installments on the last day of each calendar quarter, March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025.

3. Not applicable for Restricted Stock Units.

4. This represents a restricted stock unit award granted on March 18, 2024 that vests over a three year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two year period.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for AmirAli Talasaz	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Guardant Health insider AmirAli Talasaz report (GH)?

He reported RSU vesting and company share retentions: vested 4,814 shares on 09/30/2025 and 23,997 shares on 10/01/2025, with 2,440 and 12,162 shares retained for tax withholding at $62.48 and $62.65, respectively.

How many shares does AmirAli Talasaz beneficially own after these Form 4 transactions?

2,010,036 shares of Guardant Health common stock, as reported following the transactions.

Were the transactions open‑market purchases or compensation vesting?

The transactions were RSU vesting (compensation) and company retention of shares to cover tax withholding; the Form uses codes M (issuance on vesting) and F (retention for tax).

What amounts were withheld for taxes and at what prices?

2,440 shares withheld at $62.48 and 12,162 shares withheld at $62.65, per the Form 4 explanations.

When were the RSU awards originally granted?

The Form states the 4,814 RSUs were from a March 12, 2025 grant; the larger award vests from a March 18, 2024 grant with prior vesting noted in the filing.